deCODE genetics (Nasdaq:DCGN) today announced that
it has appointed Jakob Sigurdsson as Senior Vice President,
Corporate Development.
Mr. Sigurdsson has served for the past two years as
CEO and President of Alfesca, a multinational foods
group with major operations in Iceland, the UK, France
and Spain and annual turnover of approximately $800
million. He previously held senior positions in the
United States and Europe for Rohm and Haas Company,
a NYSE-listed specialty materials company. Mr. Sigurdsson
holds a BS degree in chemistry from the University of
Iceland and an MBA from the Kellogg School of Management
at Northwestern University.
"We welcome Jakob to deCODE. His expertise and
success in building major multinational enterprises
make him a key addition to the deCODE team. We are focused
on advancing our product development work in both drugs
and diagnostics as well as expanding our partnerships
in the global pharmaceutical industry, and Jakob will
play a vital role in executing on our strategy,"
said Kari Stefansson, CEO of deCODE.
About deCODE
deCODE genetics (NASDAQ:DCGN) is a global leader in applying human genetics
to develop drugs for common diseases. Our population approach has enabled
us to discover and target key biological pathways involved in conditions
ranging from heart attack to cancer. We are turning these discoveries into
new medicine to better treat and prevent many of the biggest challenges to
public health. deCODE is delivering on the promise of the new genetics.SM
Visit us on the web at www.decode.com.
Any statements contained in this presentation that relate to future plans,
events or performance are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, among others, those relating
to technology and product development, integration of acquired businesses,
market acceptance, government regulation and regulatory approval processes,
intellectual property rights and litigation, dependence on collaborative relationships,
ability to obtain financing, competitive products, industry trends and other
risks identified in deCODE’s filings with the Securities and Exchange Commission.
deCODE undertakes no obligation to update or alter these forward-looking statements
as a result of new information, future events or otherwise.
